Brazil Osteoarthritis Therapeutics Market Size and Share - Growth Analysis Report and Forecast Trends (2026-2035)

Brazilian clinical research is increasingly evaluating regenerative and blood-derived interventions for osteoarthritis. One of the registered clinical trials (ReBEC; 2026/09) studies randomization between hyaluronic acid intra-articular injection and Lipogems, a therapy using autologous micro-fragmented adipose tissue for knee osteoarthritis. This study is conducted by the Universidade Federal de São Paulo and Hospital Albert Einstein. The trial directly compares a conventional injectable therapy with an autologous tissue-based intervention, reflecting broader diversification within Brazil’s osteoarthritis treatment research. This development is relevant to therapeutics manufacturers because clinical investigation is moving toward therapies intended not only to manage symptoms but also to explore tissue-based approaches to joint disease.

Interventional pain management is becoming increasingly significant for patients with osteoarthritis in Brazil because of the need to control symptoms before proceeding to undergo surgery. At Hospital Federal de Ipanema, a comparative study between the conventional radiofrequency technique and the intra-articular corticosteroid injection was done on patients scheduled for knee replacement surgery under the SUS scheme. The study spanned six months during which 71 knees were monitored, and greater than 76% had reduced pain significantly. The Brazilian Ministry of Health reported the findings in July 2026. The development supports greater use of minimally invasive interventions for advanced osteoarthritis, particularly where patients require meaningful pain relief while definitive surgical treatment remains pending.

Increasingly, Brazilian scientists are beginning to look into the possibility of enhancing or replacing proven injectable treatments with autologous options. The recently registered UFSP study pits hyaluronic acid intra-articular injection versus autologous microfragmented adipose tissue in patients with knee osteoarthritis. Instead of testing hyaluronic acid injection against placebo, this study is pitting an already proven viscosupplement treatment against a tissue-based therapy. Such research may prove influential when future treatment decisions are made depending on outcome. For Brazil’s osteoarthritis therapeutics market, such comparative trials are particularly relevant because they can generate locally applicable evidence around competing injectable treatment modalities and potentially expand the range of therapies considered for patients with knee osteoarthritis, thereby shaping the growth of the Brazil osteoarthritis therapeutics market.

Evidence-based non-surgical management remains an important part of Brazil’s osteoarthritis treatment framework. The Brazilian Health Technology Assessment Commission (CONITEC) maintains its Brazilian Guideline for Non-Surgical Treatment of Knee Osteoarthritis, with the document updated on 2 July 2026. The guideline provides a national evidence-based framework for managing knee osteoarthritis without surgery. Its continued maintenance is relevant to therapeutics because treatment adoption in Brazil is influenced not only by new clinical research but also by nationally developed recommendations for patient management. Pharmaceutical and injectable-therapy companies therefore operate within an environment where treatment approaches are increasingly assessed through structured clinical-evidence and health-technology-assessment processes.

In addition, Brazil’s pipeline for osteoarthritis research is headed towards large prospective studies in regard to injectable treatments. There is one study which has been registered by ReBEC in June 2026, which aims at evaluating the effects of platelet-rich plasma in patients suffering from bilateral knee osteoarthritis, in addition to obesity and autonomic dysfunction. This trial is designed using a prospective randomised study approach, and it will enrol 160 participants between the ages of 40-70 years. Its focus on a defined patient population is important because treatment response to injectable therapies can vary according to clinical characteristics. The study therefore contributes to Brazil’s growing evidence base around patient selection and blood-derived therapies, while potentially helping researchers determine where such interventions fit within the broader management of knee osteoarthritis.